SHENG Bo,TU Quanmei,ZHU Xueqiong. A new cervical cytology brush and its clinical application in cervical cancer screening[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2018, 48(10): 731-734.
Abstract：Objective: To introduce a new type of cervical cytology brush and to investigate its clinical application in the cervical cancer screening. Methods: The structure and operating principles of this new cervical cytology brush were described in detail. Thirty women with abnormal cytology or high-risk human papillomavirus (HPV) positive via the traditional cytology brush in the Second Affiliated Hospital of Wenzhou Medical University from March 2017 to January 2018 were selected. According to instructions, samples of cervical exfoliate cells were collected using a new cytology brush later. The rates of satisfactory cytology specimen, abnormal cytology and HPV positive in two groups were evaluated. Results: The satisfaction rates of cervical cytology specimen using the new and traditional cytology brush was both 100%. Twenty-three women (76.7%) had abnormal cytology and twenty-five women (83.3%) tested high-risk HPV positive in the traditional cytology brush group. The rates of abnormal cytology and high-risk HPV positive were 63.3% and 76.7%, respectively, in the new cytology brush group. The consistency analysis showed good agreement (kappa>0.75). Conclusion: The new type of cervical cytology brush could effectively collect samples of cervical exfoliate cells. It performed similarly to the traditional cervical cytology brush in identifying abnormal cytology and high-risk HPV in cervical cancer screening. Our data suggested that the new cervical cytology brush could be an alternative, more convenient and efficient strategy for cervical cancer screening as compared to traditional cytology brush.
[1] GINSBURG O, BRAY F, COLEMAN M P, et al. The global burden of women’s cancers: a grand challenge in global health[J]. Lancet, 2017, 389(10071): 847-860.
[2] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] BASU P, MITTAL S, BHADRA VALE D, et al. Secondary prevention of cervical cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2018, 47: 73-85.
[4] DENNY L, DE SANJOSE S, MUTEBI M, et al. Interventions to close the divide for women with breast and cervical cancer between low-income and middle-income countries and high-income countries[J]. Lancet, 2017, 389(10071): 861-870.
[5] Practice Bulletin No.157: Cervical cancer screening and pre-vention[J]. Obstet Gynecol, 2016, 127(1): e1-20.
[6] KOLIOPOULOS G, NYAGA V N, SANTESSO N, et al. Cytology versus HPV testing for cervical cancer screening in the general population[J]. Cochrane Database Syst Rev, 2017, 8: CD008587.
[7] SCHIFFMAN M, CASTLE P E, JERONIMO J, et al. Human papillomavirus and cervical cancer[J]. Lancet, 2007, 370(9590): 890-907.
[8] SCHIFFMAN M, SOLOMON D. Clinical practice. Cervical-cancer screening with human papillomavirus and cytologic cotesting[J]. N Engl J Med, 2013, 369(24): 2324-2331.
[9] GOODMAN A. HPV testing as a screen for cervical cancer [J]. BMJ, 2015, 350: h2372.
[10] WRIGHT T C, STOLER M H, BEHRENS C M, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test[J]. Gynecol Oncol, 2015, 136(2): 189-197.
[11] CASTLE P E, STOLER M H, WRIGHT T C JR, et al. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study[J]. Lancet Oncol, 2011, 12(9): 880-890.
[12] WU Q, ZHAO X, FU Y, et al. A cross-sectional study on HPV testing with type 16/18 genotyping for cervical cancer screening in 11,064 Chinese women[J]. Cancer Med, 2017, 6(5): 1091-1101.
[13] MALILA N, LEINONEN M, KOTANIEMI-TALONEN L, et al. The HPV test has similar sensitivity but more overdiagnosis than the Pap test-a randomised health services study on cervical cancer screening in Finland[J]. Int J Cancer, 2013, 132(9): 2141-2147.
[14] ZHU J, NORMAN I, ELFGREN K, et al. A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer[J]. Oncol Rep, 2007, 18(1): 157-160.
[15] MASSAD L S, EINSTEIN M H, HUH W K, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors[J]. Obstet Gynecol, 2013, 121(4): 829-846.
